Skip to main content
SpringerLink
Log in

Expressing foreign genes by Newcastle disease virus for cancer therapy

  • Reviews
  • Published:
Molecular Biology Aims and scope Submit manuscript

Abstract

An interesting aspect of Newcastle disease virus (NDV) is the ability to selectively replicate in tumor cells. Recently, using reverse genetics technology to enhance the oncolytic properties and therapeutic potential of NDV for tumor therapy has become popular in immunocompetent carcinoma tumor models. Expressing foreign genes by recombinant NDV (rNDV-FG) has been shown to be more effective in cancer therapy in preclinical studies. This paper provides an overview of the current studies on the cytotoxic and anti-cancer effects of rNDV-FG via direct oncolysis and immune stimulation. Safety of rNDV-FG as a therapeutic agent for cancer immunotherapy and virotherapy is also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Soskolne C.L., Sieswerda L.E. 2010. Cancer risk associated with pulp and paper mills: A review of occupational and community epidemiology. Chronic Dis. Can. 29, 86–100.

    PubMed  Google Scholar 

  2. van der Kwast T. 2010. Words of wisdom. Re: The index lesion and focal therapy: An analysis of the pathological characteristics of prostate cancer. Eur. Urol. 58, 796–797.

    Article  PubMed  Google Scholar 

  3. Shi L., Zhou Q., Wu J., Ji M., Li G., Jiang J., Wu C. 2012. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol. Immunother. 61, 2251–2259.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Rocque G.B., Cleary J.F. 2013. Palliative care reduces morbidity and mortality in cancer. Nat. Rev. Clin. Oncol. 10, 271–282

    Google Scholar 

  5. George N.J. 1996. Incidence of prostate cancer will double by the year 2030: The argument against. Eur. Urol. 29(Suppl. 2), 298–300.

    Google Scholar 

  6. Norman K.L., Farassati F., Lee P.W. 2001. Oncolytic viruses and cancer therapy. Cytokine Growth Factor Rev. 12, 271–282.

    Article  CAS  PubMed  Google Scholar 

  7. Nguyen T.L., Wilson M.G., Hiscott J. 2010. Oncolytic viruses and histone deacetylase inhibitors: A multipronged strategy to target tumor cells. Cytokine Growth Factor Rev. 21, 153–159.

    Article  CAS  PubMed  Google Scholar 

  8. Atherton M.J., Lichty B.D. 2013. Evolution of oncolytic viruses: Novel strategies for cancer treatment. Immunotherapy. 5, 1191–1206.

    Article  CAS  PubMed  Google Scholar 

  9. van der Wall E., Rutgers E.J., Holtkamp M.J., Baars J.W., Schornagel J.H., Peterse J.L., Beijnen J.H., Rodenhuis S. 1996. Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. Br. J. Cancer. 73, 1080–1085.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274, 372–276.

    Article  Google Scholar 

  11. Garber K. 2006. China approves world’s first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 98, 298–300.

    Article  PubMed  Google Scholar 

  12. Hoption Cann S.A., van Netten J.P., van Netten C. 2003. Dr. William Coley and tumour regression: A place in history or in the future. Postgrad. Med. J. 79, 672–680.

    PubMed Central  CAS  PubMed  Google Scholar 

  13. Zamarin D., Vigil A., Kelly K., Garcia-Sastre A., Fong Y. 2009. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Therapy. 16, 796–804.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Smyth M.J., Hayakawa Y., Takeda K., Yagita H. 2002. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer. 2, 850–861.

    Article  CAS  PubMed  Google Scholar 

  15. Yeap S.K., Alitheen N.B., Ali A.M., Omar A.R., Raha A.R., Suraini A.A., Muhajir A.H. 2007. Effect of Rhaphidophora korthalsii methanol extract on human peripheral blood mononuclear cell (PBMC) proliferation and cytolytic activity toward HepG2. J. Ethnopharmacol. 114, 406–411.

    Article  CAS  PubMed  Google Scholar 

  16. Sinkovics J.G., Horvath J.C. 2000. Newcastle disease virus (NDV): Brief history of its oncolytic strains. J. Clin. Virol. 16, 1–15.

    Article  CAS  PubMed  Google Scholar 

  17. Liu L. 2014. Book Review: Fields Virology, 6th Edition. Clin. Inf. Diseases, 136–145.

    Google Scholar 

  18. Zhao H.Y., Chen H.W., Qian X.H., Hu X.C. 2011. Preparation of polyclonal antibody of recombinant human thioredoxin-1 and its protective effects on neonatal rats with endotoxemia. Chinese J. Contemp. Pediatr. 13, 837–841.

    CAS  Google Scholar 

  19. Connaris H., Takimoto T., Russell R., Crennell S., Moustafa I., Portner A., Taylor G. 2002. Probing the sialic acid binding site of the hemagglutininneuraminidase of Newcastle disease virus: Identification of key amino acids involved in cell binding, catalysis, and fusion. J. Virol. 76, 1816–1824.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Toyoda T., Sakaguchi T., Imai K., Inocencio N.M., Gotoh B., Hamaguchi M., Nagai Y. 1987. Structural comparison of the cleavage-activation site of the fusion glycoprotein between virulent and avirulent strains of Newcastle disease virus. Virology. 158, 242–247.

    Article  CAS  PubMed  Google Scholar 

  21. Walter R.J., Attar B.M., Rafiq A., Delimata M., Tejaswi S. 2012. Two avirulent, lentogenic strains of Newcastle disease virus are cytotoxic for some human pancreatic tumor lines in vitro. J. Pancreas. 13, 502–513.

    Google Scholar 

  22. Prestwich R.J., Errington F., Harrington K.J., Pandha H.S., Selby P., Melcher A. 2008. Oncolytic viruses: Do they have a role in anti-cancer therapy?. Clin. Med. Oncol. 2, 83–96.

    PubMed Central  CAS  PubMed  Google Scholar 

  23. Cho S.H., Kwon H.J., Kim T.E., Kim J.H., Yoo H.S., Park M.H., Park Y.H., Kim S.J. 2008. Characterization of a recombinant Newcastle disease virus vaccine strain. Clin. Vaccine Immunol. 15, 1572–1579.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Krishnamurthy S., Takimoto T., Scroggs R.A., Portner A. 2006. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J. Virol. 80, 5145–5155.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Cassel W.A., Garrett R.E. 1965. Newcastle disease virus as an antineoplastic agent. Cancer. 18, 863–868.

    Article  CAS  PubMed  Google Scholar 

  26. Murray D.R., Cassel W.A., Torbin A.H., Olkowski Z.L., Moore M.E. 1977. Viral oncolysate in the management of malignant melanoma: 2. Clinical studies. Cancer. 40, 680–686.

    CAS  Google Scholar 

  27. Peeters B.P., de Leeuw O.S., Koch G., Gielkens A.L. 1999. Rescue of Newcastle disease virus from cloned cDNA: Evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 73, 5001–5009.

    PubMed Central  CAS  PubMed  Google Scholar 

  28. Bai F., Niu Z., Tian H., Li S., Lv Z., Zhang T., Ren G., Li D. 2014. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Immunol. Lett. 159, 36–46.

    Article  PubMed  Google Scholar 

  29. Niu Z., Bai F., Sun T., Tian H., Yu D., Yin J., Li S., Li T., Cao H., Yu Q., Wu Y., Ren G., Li D. 2014. Recombinant Newcastle disease virus expressing IL15 demonstrates promising antitumor efficiency in melanoma model. Technol. Cancer Res. Treatment. 72–78.

    Google Scholar 

  30. Zhao H., Janke M., Fournier P., Schirrmacher V. 2008. Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Virus Res. 136, 75–80.

    Article  CAS  PubMed  Google Scholar 

  31. Zhang X., Liu H., Liu P., Peeters B.P., Zhao C., Kong X. 2013. Recovery of avirulent, thermostable Newcastle disease virus strain NDV4-C from cloned cDNA and stable expression of an inserted foreign gene. Arch. Virol. 158, 2115–2120.

    Article  CAS  PubMed  Google Scholar 

  32. Zorn U., Dallmann I., Grosse J., Kirchner H., Poliwoda H., Atzpodien J. 1994. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother. 9, 225–235.

    Article  CAS  PubMed  Google Scholar 

  33. Ghrici M., El Zowalaty M., Omar A.R., Ideris A. 2013. Induction of apoptosis in MCF-7 cells by the hemag-glutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240. Oncol. Rep. 30, 1035–1044.

    PubMed Central  CAS  PubMed  Google Scholar 

  34. Fournier P., Zeng J., Schirrmacher V. 2003. Two ways to induce innate immune responses in human PBMCs: Paracrine stimulation of IFN-alpha responses by viral protein or dsRNA. Int. J. Oncol. 23, 673–680.

    CAS  PubMed  Google Scholar 

  35. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. 1999. Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189–220.

    Article  CAS  PubMed  Google Scholar 

  36. Sato K., Hida S., Takayanagi H., Yokochi T., Kayagaki N., Takeda K., Yagita H., Okumura K., Tanaka N., Taniguchi T., Ogasawara K. 2001. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur. J. Immunol. 31, 3338–3346.

    Article  Google Scholar 

  37. van Dommelen S.L., Tabarias H.A., Smyth M.J., Degli-Esposti M.A. 2003. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J. Virol. 77, 1877–1884.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Jarahian M., Watzl C., Fournier P., Arnold A., Djandji D., Zahedi S., Cerwenka A., Paschen A., Schirrmacher V., Momburg F. 2009. Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase. J. Virol. 83, 8108–8121.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Washburn B., Weigand M.A., Grosse-Wilde A., Janke M., Stahl H., Rieser E., Sprick M.R., Schirrmacher V., Walczak H. 2003. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J. Immunol. 170, 1814–1821.

    Article  CAS  PubMed  Google Scholar 

  40. Bai F.L., Tian H., Yu Y.H., Yin J.C., Ren G.P., Zhou B., Li D.S. 2014. TNF-related apoptosis-inducing ligand delivered by rNDV is a novel agent for cancer gene therapy. Technol. Cancer Res. Treat. June 30 [Epub ahead of print].

    Google Scholar 

  41. Janke M., Peeters B., de Leeuw O., Moorman R., Arnold A., Fournier P., Schirrmacher V. 2007. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther. 14, 1639–1649.

    Article  CAS  PubMed  Google Scholar 

  42. Zamarin D., Martinez-Sobrido L., Kelly K., Mansour M., Sheng G., Vigil A., Garcia-Sastre A., Palese P., Fong Y. 2009. Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol. Ther. 17, 697–706.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Elankumaran S. 2013. Genetically engineered Newcastle disease virus for prostate cancer: A magic bullet or a misfit. Exp. Rev. Anticancer Ther. 13, 769–772.

    Article  CAS  Google Scholar 

  44. Janke M., Peeters B., Zhao H., de Leeuw O., Moorman R., Arnold A., Ziouta Y., Fournier P., Schirrmacher V. 2008. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int. J. Oncol. 33, 823–832.

    CAS  PubMed  Google Scholar 

  45. Altomonte J., Marozin S., Schmid R.M., Ebert O. 2010. Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol. Ther. 18, 275–284.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Vigil A., Martinez O., Chua M.A., Garcia-Sastre A. 2008. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol. Ther. 16, 1883–1890.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Vigil A., Park M.S., Martinez O., Chua M.A., Xiao S., Cros J.F., Martinez-Sobrido L., Woo S.L., Garcia-Sastre A. 2007. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 67, 8285–8292.

    Article  CAS  PubMed  Google Scholar 

  48. Puhler F., Willuda J., Puhlmann J., Mumberg D., Romer-Oberdorfer A., Beier R. 2008. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Gene Ther. 15, 371–383.

    Article  CAS  PubMed  Google Scholar 

  49. Schirrmacher V., Griesbach A., Ahlert T. 2001. Antitumor effects of Newcastle disease virus in vivo: Local versus systemic effects. Int. J. Oncol. 18, 945–952.

    CAS  PubMed  Google Scholar 

  50. Freeman A.I., Zakay-Rones Z., Gomori J.M., Linetsky E., Rasooly L., Greenbaum E., Rozenman-Yair S., Panet A., Libson E., Irving C.S., Galun E., Siegal T. 2006. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13, 221–228.

    Article  CAS  PubMed  Google Scholar 

  51. Ertel C., Millar N. S., Emmerson P.T., Schirrmacher V., von Hoegen P. 1993. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur. J. Immunol. 23, 2592–2596.

    Article  CAS  PubMed  Google Scholar 

  52. von Hoegen P., Zawatzky R., Schirrmacher V. 1990. Modification of tumor cells by a low dose of Newcastle disease virus: 3. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta. Cell. Immunol. 126, 80–90.

    Article  Google Scholar 

  53. Pecora A.L., Rizvi N., Cohen G.I., Meropol N.J., Sterman D., Marshall J.L., Goldberg S., Gross P., O’Neil J.D., Groene W.S., Roberts M.S., Rabin H., Bamat M.K., Lorence R.M. 2002. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20, 2251–2266.

    Article  CAS  PubMed  Google Scholar 

  54. Zeng J., Fournier P., Schirrmacher V. 2002. Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology. 297, 19–30.

    Article  CAS  PubMed  Google Scholar 

  55. Schirrmacher V., Ahlert T., Probstle T., Steiner H.H., Herold-Mende C., Gerhards R., Hagmuller E. 1998. Immunization with virus-modified tumor cells. Semin. Oncol. 25, 677–696.

    CAS  PubMed  Google Scholar 

  56. Schirrmacher V., Haas C., Bonifer R., Ahlert T., Gerhards R., Ertel C. 1999. Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 6, 63–73.

    Article  CAS  PubMed  Google Scholar 

  57. DiNapoli J.M., Kotelkin A., Yang L., Elankumaran S., Murphy B.R., Samal S.K., Collins P.L., Bukreyev A. 2007. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc. Natl. Acad. Sci. U. S. A. 104, 9788–9793.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Nelson N.J. 1999. Scientific interest in Newcastle disease virus is reviving. J. Natl. Cancer Inst. 91, 1708–1710.

    Article  CAS  PubMed  Google Scholar 

  59. Reichard K.W., Lorence R.M., Cascino C.J., Peeples M.E., Walter R.J., Fernando M.B., Reyes H.M., Greager J.A. 1992. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 52, 448–453.

    Article  CAS  PubMed  Google Scholar 

  60. Lorence R.M., Katubig B.B., Reichard K.W., Reyes H.M., Phuangsab A., Sassetti M.D., Walter R.J., Peeples M.E. 1994. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 54, 6017–6021.

    CAS  PubMed  Google Scholar 

  61. Apostolidis L., Schirrmacher V., Fournier P. 2007. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int. J. Oncol. 31, 1009–1019.

    CAS  PubMed  Google Scholar 

  62. Nagai Y., Hamaguchi M., Toyoda T. 1989. Molecular biology of Newcastle disease virus. Progr. Vet. Microbiol. Immunol. 5, 16–64.

    CAS  Google Scholar 

  63. Sarkar K., Goswami S., Roy S., Mallick A., Chakraborty K., Bose A., Baral R. 2010. Neem leaf glycoprotein enhances carcinoembryonic antigen presentation of dendritic cells to T and B cells for induction of anti-tumor immunity by allowing generation of immune effector/memory response. Int. Immunopharmacol. 10, 865–874.

    Article  CAS  PubMed  Google Scholar 

  64. Schulze T., Kemmner W., Weitz J., Wernecke K.D., Schirrmacher V., Schlag P.M. 2009. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: Results of a prospective randomized trial. Cancer Immunol. Immunother. 58, 61–69.

    Article  CAS  PubMed  Google Scholar 

  65. Ockert D., Schirrmacher V., Beck N., Stoelben E., Ahlert T., Flechtenmacher J., Hagmuller E., Buchcik R., Nagel M., Saeger H.D. 1996. Newcastle disease virusinfected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res. 2, 21–28.

    CAS  PubMed  Google Scholar 

  66. Karcher J., Dyckhoff G., Beckhove P., Reisser C., Brysch M., Ziouta Y., Helmke B.H., Weidauer H., Schirrmacher V., Herold-Mende C. 2004. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 64, 8057–8061.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Life Science, Northeast Agricultural University, Harbin, 150030, China

    F. L. Bai, G. P. Ren & D. S. Li

  2. Research and Development Department, Lubin Environmental Equipment Protection Co., Ltd, Shanghai, 200125, China

    F. L. Bai & H. Tian

  3. Southeast Poultry Research Laboratory, Agricultural Research Service, United States Department of Agriculture, 934 College Station Road, Athens, GA, 30605, USA

    Q. Z. Yu

Authors
  1. F. L. Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Q. Z. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. P. Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. S. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. S. Li.

Additional information

Published in Russian in Molekulyarnaya Biologiya, 2015, Vol. 49, No. 2, pp. 195–204.

The article is published in the original.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bai, F.L., Tian, H., Yu, Q.Z. et al. Expressing foreign genes by Newcastle disease virus for cancer therapy. Mol Biol 49, 171–178 (2015). https://doi.org/10.1134/S0026893315020028

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0026893315020028

Keywords

Search

Navigation